Stargardt Disease — Deal Benchmarks & Valuation
Market Analysis
Stargardt Disease is one of the most actively transacted indications in ophthalmology licensing. Phase 1 deals for stargardt disease carry a median total deal value of $1.9B, with upfront payments ranging from $127M to $440M. The recommended deal structure allocates approximately 14% to upfront payments and 86% to milestones.
Milestone structures for stargardt disease deals allocate $533M to development milestones, $466M to regulatory milestones, and $666M to commercial milestones. Royalty rates range from 8% to 16% at the base tier, with tiered escalation reaching 12%-20% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for stargardt disease licensing?
What royalty rates are standard for stargardt disease deals?
How are stargardt disease deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.